Improving environmental protection in EU pharmaceutical legislation
Improving environmental protection in EU pharmaceutical legislation
Recommendations for reducing adverse environmental impacts from human pharmaceuticals
Herausgeber
Quelle
Schlagwörter
Umweltrisikobewertung, pharmaceuticals, environmental risk assessment
Forschungskennzahl (FKZ)
Verbundene Publikation
Zitation
GILDEMEISTER, Daniela, Annika BUCK, Arne HEIN, Ines RÖNNEFAHRT, Ina EBERT und Malgorzata DEBIAK, 2022. Improving environmental protection in EU pharmaceutical legislation [online]. Dessau-Roßlau: Umweltbundesamt. Scientific Opinion Paper. Verfügbar unter: https://openumwelt.de/handle/123456789/2585
Zusammenfassung englisch
In preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (UBA) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA's experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach. Quelle: www.umweltbundesamt.de